SAGE Open Medical Case Reports · 2023 · 10 citations · 5 references
MedicineDermatologyOncologyCancer ImmunologyCutaneous OncologyImmunotherapyCancer ImmunotherapyCheckpoint Inhibitor TherapyImmune Checkpoint InhibitorsImmune-related Adverse Event ManagementImmune-related Adverse EventsImmunotherapy For Skin CancerCase Series ReviewImmune Checkpoint Inhibitor ResponseImmune Checkpoint Inhibitor TherapyImmune-mediated Adverse EventsInterleukin 23 InhibitionInterleukin-23 InhibitorsMelanoma ProgressionPsoriatic Disease
Immune checkpoint inhibitors have revolutionized cancer treatment but can induce immune-related adverse events including psoriasis. Managing immune-related psoriasis or psoriasis in a cancer setting is challenging with a lack of safety data. We describe three patients receiving interleukin-23 inhibitors to manage psoriasis in an active cancer setting, including one with immune-related psoriasis. Interleukin-23 inhibitors were effective for all patients. While being on interleukin-23 inhibitors, one patient had cancer partial response, one had deep partial response but then progressed and died from her melanoma, and one suffered melanoma progression.
5
Igor Puzanov, Adi Diab, K. Abdallah et al. · Journal for ImmunoTherapy of Cancer · 2017 · 2K citations · Full text
Life Sciences, Immunology, Oncology +17
Adverse Effects of Low-Dose Methotrexate
Daniel H. Solomon, Robert J. Glynn, Elizabeth W. Karlson et al. · Annals of Internal Medicine · 2020 · 222 citations · Full text
Andrew Blauvelt, Tsen‐Fang Tsai, Richard G. Langley et al. · Journal of the American Academy of Dermatology · 2021 · 59 citations